Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Depreciation & Amortization (CF) (2024 - 2026)

Evommune (EVMN) reported Depreciation & Amortization (CF) of $349000.0 for Q1 2026, down 7.43% year-over-year from $377000.0 in Q1 2025, and up 7.06% on a QoQ basis from $326000.0 in Q4 2025.

Evommune (EVMN) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $349000.0 in Q1 2026.

  • Quarterly Depreciation & Amortization (CF) fell 7.43% year-over-year to $349000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (changed N/A YoY) and the FY2025 annual result came in at $1.4 million, up 7.93% from the prior year.
  • Depreciation & Amortization (CF) improved to $349000.0 in Q1 2026 per EVMN's latest filing, from $326000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $377000.0 in Q1 2025 and bottomed at $326000.0 in Q4 2025.
  • The 3-year median for Depreciation & Amortization (CF) is $354500.0 (2024), against an average of $353000.0.
  • The widest annual swing landed in 2025, when Depreciation & Amortization (CF) fell 9.44%; it then retreated 7.43% in 2026.
  • Tracing EVMN's Depreciation & Amortization (CF) over 3 years: stood at $360000.0 in 2024, then slipped by 9.44% to $326000.0 in 2025, then grew by 7.06% to $349000.0 in 2026.
  • Per Business Quant, the three latest EVMN Depreciation & Amortization (CF) figures stand at $349000.0 (Q1 2026), $326000.0 (Q4 2025), and $377000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 13.55 Mn
10 Evommune 744.11 Mn 532.65 Mn - 349,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 349,000.00
Mar 31, 2026 349,000.00
Dec 31, 2025 326,000.00
Dec 31, 2025 326,000.00
Mar 31, 2025 377,000.00
Mar 31, 2025 377,000.00
Dec 31, 2024 360,000.00
Dec 31, 2024 360,000.00